Navigation Links
VirtualScopics Receives NASDAQ Delisting Notice; Company Files Appeal to Stay Delisting

ROCHESTER, N.Y., Aug. 11 /PRNewswire-FirstCall/ -- VirtualScopics, Inc. (Nasdaq: VSCP), leading provider of quantitative imaging for clinical trials, today announced that on August 7, 2008, it received notification from The NASDAQ Stock Market that the Company remains out of compliance with the $1.00 minimum per share bid requirement for continued listing as set forth in NASDAQ Marketplace Rule 4310(c)(4). As a result, VirtualScopics' securities are subject to delisting from The NASDAQ Capital Market.

In response to the notification, the Company has filed an appeal of the Staff Determination to a NASDAQ Listings Qualification Panel. The appeal request will automatically stay the delisting until the Panel reaches a decision. NASDAQ will typically hold a hearing to consider an appeal within 45 days after the appeal is made, and it may take up to 30 days after the hearing to make a decision. At the hearing, VSCP intends to present a plan to regain compliance with the minimum bid price requirement in order to maintain its NASDAQ listing. There can be no assurance the Panel will grant the Company's request for continued listing.

VSCP anticipates that its plan will consist of a request for additional time, not to exceed 180 days from August 6, 2008, for the Company to regain compliance without effecting a reverse stock split, provided that if the Company does not achieve compliance by a certain date within this additional time, the Company will effect a reverse split. Under Delaware law, the Company can effect a reverse stock split by obtaining stockholder approval, which the Company received on May 8, 2008 at its Annual Meeting of Stockholders.

"Maintaining our NASDAQ Capital Market listing is important to the Company's visibility and building of long-term sustainable value for stockholders," said Jeff Markin, VirtualScopics' President and Chief Executive Officer. "Ensuring compliance with the NASDAQ listing requirements was the principal reason our stockholders approved the reverse split in the event we are unable to otherwise regain listing compliance." He further added, "We remain confident in our long-term strategy. We are encouraged by the progress we have made in recent quarters, particularly within our operations and new contract awards. We anticipate this momentum will continue as the year progresses."

About VirtualScopics, Inc.

VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics' industry- leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit

Forward-Looking Statements

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company's investment in infrastructure and new customer contract signings and awards in 2008 statements regarding maintaining listing on the Nasdaq Capital Market, and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to contact awards, the risk that they may not get signed and risk that we may be delisted from the Nasdaq Capital Market. Other risks include the company's dependence on its largest customers and risks of contract performance, protection of our intellectual property and the risks of infringement of the intellectual property rights of others. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.

CONTACT: Molly Henderson

Chief Business and Financial Officer

500 Linden Oaks

Rochester, New York 14625

(585) 249.6231

SOURCE VirtualScopics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. VirtualScopics Announces $4.35 Million Private Placement
2. VirtualScopics Backlog Exceeds a Record $20 Million
3. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
4. DaVita Receives Civil Complaint
5. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
6. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
7. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
8. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
9. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
10. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
11. Prime Therapeutics Receives TIPPS Certification
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 , ... At Grand Dental ... and convenient setting. , When you have dental problems, you need to turn to ... can effectively diagnose and treat your needs, a friendly dentist who counsels you on ...
(Date:11/30/2015)... ... , ... Using a combination of two blood sugar tests rather than a ... a new study by researchers at the School of Public Health at Georgia State ... of Blood Glucose Tests ,” published in Frontiers in Public Health, the researchers noted ...
(Date:11/30/2015)... ... November 30, 2015 , ... Newly ... out of Glen Ridge, NJ. He has both advanced training and considerable ... He is also an expert in cosmetic dentistry. He is an active ...
(Date:11/30/2015)... ... 2015 , ... International telepathology consultations can significantly improve patient ... Diagnostics researchers. Their review of more than 1,500 pathology cases submitted electronically ... significantly altered treatment plans for more than half of the cases in which ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ”Dying Words: The ... be released on December 1, 2015, to coincide with World AIDS Day. The multi-media ... journalist who covered the AIDS epidemic as he was dying of the disease. , ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... November 30, 2015 global cell culture market ... bn to US$11.3 bn by 2022 at a CAGR of 7.1% ... to grow from its 2013 value of US$6.1 bn to US$11.3 ... Transparency Market Research has announced the release of a new ... the report, titled ,Cell Culture Market - Global Industry Analysis, Size, ...
(Date:11/30/2015)...   Royal Philips (NYSE: PHG ... MRI guided user interface and automatic scan parameter selection ... Conditional implants, such as knee and hip replacements, spine ... of North America Annual Meeting (RSNA) . The new ... of this growing patient population. ScanWise Implant adds to ...
(Date:11/30/2015)... RATON, Fla. , Nov. 30, 2015   ... (the Institute) announced today that it has finalized ... device start-up company with technology developed at Florida State ... publicly-funded research, and bridges early funding gaps for companies ... and research institutions. --> ...
Breaking Medicine Technology: